Water soluble prodrugs of the antitumor agent 3-[(3-amino-4-methoxy)phenyl]-2-(3,4,5-trimethoxyphenyl)cyclopent-2-ene-1-one

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 6, 2003, Pages 1021-1029

  Nam, Nguyen Hai ^a,c   Kim, Yong ^a   You, Young Jae ^a   Hong, Dong Ho ^a,b   Kim, Hwan Mook ^b   Ahn, Byung Zun ^a  

^a Chungnam National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 4 AMINOBUTYRIC AMIDE; 1 4 AMINOMETHYLBENZOIC AMIDE; 1 4 BIS(2 CHLOROETHYL)AMINOPHENYLALANINE; 1 6 AMINOHEXANOIC AMIDE; 1 [3 [2' (DIBENZYLOXYPHOSPHONO)OXY 4',6' DIMETHYLPHENYL] 3,3 DIMETHYLPROPIONIC]AMIDE; 1 [3 [2' (DIHYDROXYPHOSPHONO)OXY 4',6' DIMETHYLPHENYL] 3,3 DIMETHYLPROPIONIC]AMIDE; 1 ALANINE; 1 BETA ALANINE; 1 CYSTEINE; 1 DEXTRO ALANINE; 1 DIBENZYLOXYPHOSPHORAMIDATE; 1 DIHYDROXYPHOSPHORAMIDATE; 1 GLYCINE; 1 LYSINE; 1 PHENYLALANINE; 1 SERINE; 3 [(3 AMINO 4 METHOXY)PHENYL] 2 (3,4,5 TRIMETHOXYPHENYL)CYCLOPENT 2 EN 1 ONE; AMINO ACID; ANTINEOPLASTIC AGENT; DOXORUBICIN; ETOMIDATE; ETOPOSIDE; MELPHALAN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPENTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA, EXPERIMENTAL; MICE; PRODRUGS; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0037333833     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(02)00514-X     Document Type: Article

References (20)

1. Nam N. H., Kim Y., You Y. J., Hong D. H., Kim H. M., Ahn B. Z. Bioorg. Med. Chem. Lett. 12:2002;1955.
2. Bundgaard, H. In A Textbook of Drug Design and Development; Larsen, P. K., Bundgaard, H., Eds; Harwood Academic: Swizerland, 1982, p. 1-39.
3. Bundgaard H. Drugs of the Future. 16:1991;443.
4. Kearney A. S., Stella V. J. Pharm. Res. 9:1992;497.
5. Rose W. C. Anti-cancer Drugs. 3:1992;311.
6. Safadi M., Oliyai R., Stella V. J. Pharm. Res. 10:1993;1350.
7. Amsberry K. L., Gerstenberger A. E., Borchardt R. T. Pharm. Res. 8:1991;455.
8. Amsberry K. L., Borchardt R. T. Pharm. Res. 8:1991;323.
9. Golik J., Wong H.S.L., Chen S.H., Doyle T.W., Wright J.J.K., Knipe J., Rose W.C., Casazza A.M., Vyas D.M. Bioorg. Med. Chem. Lett. 15:1996;1837.
10. Wang B., Zhang H., Wang W. Bioorg. Med. Chem. Lett. 6:1996;945.
11. Wang B., Wang W., Zhang H., Shan D., Smith T. D. Bioorg. Med. Chem. Lett. 6:1996;2823.
12. Wang B., Zhang H., Zheng A., Wang W. Bioorg. Med. Chem. 6:1996;417.
13. Wang B., Liao Y. Bioorg. Med. Chem. Lett. 9:1999;1795.
14. Zheng A., Wang W., Zhang H., Wang B. Tetrahedron. 55:1999;4237.
15. Nicolaou M. G., Yuan C. S., Borchardt R. T. J. Org. Chem. 61:1996;8636.
16. Upshall D. G., Gouldstone S. J., Macey N., Maidment M. P., West S. J., Yeadon M. J. Biopharm. Sci. 1:1990;111.
17. Ohsumi K., Hatanaka T., Nakagawa R., Fukuda Y., Morinaga Y., Suga Y., Nihei Y., Ohishi K., Akiyama Y., Tsuji T. Anticancer Drug Des. 14:1999;539.
18. Skehan P., Storeng R., Scudiero D., Monk A., MacMahon J., Vistica D., Warren J., Bokesch H., Kenny S., Boyd M. R. J. Nat. Cancer Inst. 82:1990;1107.
19. Nam, N. H.; You, Y. J.; Kim, Y.; Hong, D. H.; Kim, H. M.; Ahn, B. Z. Phytother. Res. In press.
20. Kim Y., Kim S. B., You Y. J., Ahn B. Z. Planta Med. 68:2002;271.